Cytek Biosciences Q1 2024 Adj EPS $(0.05) Misses $(0.04) Estimate, Sales $44.900M Beat $43.586M Estimate
Author: Benzinga Newsdesk | May 08, 2024 04:08pm
Cytek Biosciences (NASDAQ:
CTKB) reported quarterly losses of $(0.05) per share which missed the analyst consensus estimate of $(0.04) by 25 percent. The company reported quarterly sales of $44.900 million which beat the analyst consensus estimate of $43.586 million by 3.01 percent. This is a 21.06 percent increase over sales of $37.088 million the same period last year.
Posted In: CTKB